Former GE exec takes the reins at Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals (MIP) has hired Daniel L. Peters, formerly president and CEO of GE Healthcare Medical Diagnostics division, as its new president and CEO.
John Babich, MD, MIP's CEO, will continue in his role as chief scientific officer and board member, and also will assume the roles of executive vice president and president of research and development. The Cambridge, Mass.-based company said that Babich will continue his leadership responsibilities for its scientific strategy, as well as continue the expansion and clinical development of the pipeline of radiopharmaceutical compounds.
At GE Medical Diagnostics, Peters had responsibility for business aspects, including long-term growth strategies, marketing, sales, business development, research and development (R&D) and manufacturing. Under his leadership, the radiopharmaceutical business of Amersham Health was also successfully integrated into GE Healthcare, taking the more descriptive name of Medical Diagnostics.
Prior to joining GE Healthcare, Peters had been chief operating officer of Amersham where he had global operational responsibilities. While at Amersham, Peters played a role in recruiting new talent to strengthen the R&D organization and in reorganizing the business structure to place more focus on emerging markets. Earlier, Peters was president of Nycomed Amersham, a North and South America diagnostic and therapeutic pharmaceutical subsidiary.
John Babich, MD, MIP's CEO, will continue in his role as chief scientific officer and board member, and also will assume the roles of executive vice president and president of research and development. The Cambridge, Mass.-based company said that Babich will continue his leadership responsibilities for its scientific strategy, as well as continue the expansion and clinical development of the pipeline of radiopharmaceutical compounds.
At GE Medical Diagnostics, Peters had responsibility for business aspects, including long-term growth strategies, marketing, sales, business development, research and development (R&D) and manufacturing. Under his leadership, the radiopharmaceutical business of Amersham Health was also successfully integrated into GE Healthcare, taking the more descriptive name of Medical Diagnostics.
Prior to joining GE Healthcare, Peters had been chief operating officer of Amersham where he had global operational responsibilities. While at Amersham, Peters played a role in recruiting new talent to strengthen the R&D organization and in reorganizing the business structure to place more focus on emerging markets. Earlier, Peters was president of Nycomed Amersham, a North and South America diagnostic and therapeutic pharmaceutical subsidiary.